Vivos Inc. Achieves Record Growth in IsoPet® Animal Cancer Treatments in Q1 2025

Rhea-AI Summary

Vivos Inc. (OTCQB: RDGL) reported record-breaking growth in its IsoPet® Animal Cancer Division for Q1 2025. The company's Precision Radionuclide Therapy™ treated 15 pets, marking a 150% year-over-year increase in treatment volume.

Key achievements include:

• Expansion to 14 certified clinics (8 small animal, 6 equine) with three new additions in Q1
• Breakthrough treatments in equine oncology, including four horses with ocular squamous cell carcinoma
• Biweekly production schedule of yttrium-90 hydrogel ensuring steady treatment supply
• Notable treatments at facilities like NorthStar Vets (NJ) and Brazos Equine Hospital (TX)

The company operates in the global veterinary oncology market, valued at $1.18 billion in 2023, with projected 11.3% CAGR through 2030. IsoPet® offers a non-invasive, single-session outpatient approach, positioning itself as a cost-competitive alternative to traditional radiation.

Positive

• Record 150% year-over-year increase in treatment volume (15 pets in Q1 2025)
• Expansion to 14 certified clinics from successful activation of 3 new facilities
• Operating in growing market valued at $1.18B with 11.3% CAGR through 2030
• Successful treatment expansion into equine oncology with novel applications

Negative

• None.

Kennewick, WA, April 23, 2025 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), a leader in innovative cancer therapies, announced today a record-breaking first quarter for its IsoPet^® Animal Cancer Division. The company’s patented Precision Radionuclide Therapy^™ (PRnT^™) treated an unprecedented number of pets in Q1 2025, marking a 150% year-over-year increase in treatment volume. This milestone underscores IsoPet^®’s growing role as a transformative, non-invasive solution for veterinary oncology.

Q1 2025 Highlights

1. Surge in Treatment Volume

IsoPet^® treated 15 pets in Q1 2025, a 150% increase from Q1 2024, with a robust pipeline for Q2. Treatments are facilitated by a biweekly production schedule, ensuring a steady supply of yttrium-90 (Y-90) hydrogel for precise, targeted radiation. Recent activity includes five pets treated in New Jersey and Texas during the week of April 14–18, 2025, at certified clinics like NorthStar Vets (Robbinsville, NJ) and Brazos Equine Hospital (TX). The therapy’s single-session, outpatient approach minimizes stress for pets and owners, with prior cases demonstrating significant tumor reduction and improved quality of life.

2. Breakthrough Clinical Applications

IsoPet^® achieved groundbreaking advancements in equine oncology, treating four horses with ocular squamous cell carcinoma (SCC), including two with direct cornea injections—a novel approach for a condition with limited treatment options due to its sensitive location and high recurrence rate. Additional applications include palliative therapy for advanced equine jaw cancer and margin therapy post-tumor resection to reduce recurrence. These successes build on prior outcomes, such as a horse treated in 2022 that showed significant tumor atrophy within three months and a ferret successfully treated in 2024.

3. Clinic Expansion for Greater Access

Vivos Inc. activated three new certified clinics in Q1 2025, bringing the total to 14 (8 small animal, 6 equine). New additions include:

• Brazos Equine Hospital (Texas) – Specializing in equine cancers.
• Sumner Veterinary Hospital (Washington) – Focused on small animals.
• Animal Emergency & Specialty Center (Tennessee) – Serving small animals.
The company aims to “blanket the USA” with additional clinics in 2025, ensuring reasonable driving access for pet owners. Certified veterinarians, trained in precise Y-90 injections, are pivotal to IsoPet^®’s success, as seen in treatments at Vista Veterinary Hospital (WA) and University of Missouri.

4. Strategic Marketing and Community Engagement

IsoPet^® amplified its presence at major veterinary conferences, including VMX (Orlando) and WVC (Las Vegas), with plans to attend ACVIM, PacVet, VCS, and ACVS in 2025. Targeted newsletters and direct email campaigns have driven a measurable increase in treatment inquiries, while social media engagement, including posts by @IsoPetForCancer on X, highlights ongoing treatments and veterinary expertise. Community support is evident in user recommendations on X, with pet owners praising IsoPet^®’s non-surgical approach.

5. Positioning in a Growing Market

The global veterinary oncology market, valued at $1.18 billion in 2023, is projected to grow at a 11.3% CAGR through 2030, driven by 6 million annual cancer diagnoses in U.S. dogs and cats, plus rising cases in equines and exotic animals. IsoPet^®’s minimally invasive therapy, covered by some pet insurance providers, is well-positioned to meet this demand, offering a patient friendly cost-competitive alternative to traditional radiation.

Leadership Perspective

Dr. Michael K. Korenko, President & CEO of Vivos Inc., stated:

“IsoPet^® is transforming veterinary oncology by delivering safe, effective treatments that prioritize animal welfare. Our Q1 2025 achievements reflect a tipping point, fueled by word-of-mouth from satisfied veterinarians and pet owners, as well as growing international interest. We are committed to expanding access and exploring new applications. Our operational discipline is positioning our Isopet^® division as a self-sufficient entity, which we believe is essential to maximize shareholder value. We are excited about the potential for strategic partnerships to elevate this division and accelerate growth.”

About IsoPet^®

IsoPet^® is a non-invasive, outpatient therapy that delivers high-dose beta radiation directly to solid tumors using Y-90 hydrogel. Suitable for cats, dogs, horses, and exotic animals, it targets cancers like sarcomas and equine sarcoids, with prior cases achieving complete tumor destruction and significant shrinkage. Certified clinics, rigorous vet training, and ongoing research ensure its efficacy and safety.

Pet owners seeking innovative cancer treatments can visit www.isopet.com to locate certified clinics, submit inquiries, or subscribe to our newsletter. Follow @IsoPetForCancer on X for real-time updates on treatments and advancements.
Contact Information

Michael K. Korenko, Sc.D.
President & CEO, Vivos Inc.
Email: MKorenko@RadioGel.com
Phone: (509) 736-4000
Website: www.isopet.com
Social Media: @VivosIncUSA, @IsoPetForCancer

Safe Harbor Statement

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, identified by terms such as “will,” “expects,” “plans,” “anticipates,” and “intends.” These statements involve risks and uncertainties that may cause actual results to differ materially, including challenges in executing business strategies, economic conditions, competition, regulatory changes, delays in clinic certifications, and other factors beyond Vivos Inc.’s control. For a detailed discussion of these risks, refer to the company’s filings with the Securities and Exchange Commission.

FAQ

What is the growth rate of IsoPet® treatments for RDGL in Q1 2025?

IsoPet® treatments grew 150% year-over-year in Q1 2025, treating 15 pets compared to Q1 2024.

How many certified clinics does RDGL's IsoPet® have as of Q1 2025?

RDGL has 14 certified clinics (8 small animal, 6 equine) after adding three new facilities in Q1 2025.

What is the market potential for RDGL's veterinary oncology services?

The global veterinary oncology market is valued at $1.18 billion (2023) with 11.3% CAGR through 2030, driven by 6 million annual cancer diagnoses in U.S. pets.

What new breakthrough treatments did RDGL's IsoPet® achieve in Q1 2025?

IsoPet® treated four horses with ocular squamous cell carcinoma, including two pioneering direct cornea injections.

How frequently does RDGL produce IsoPet® treatment materials?

RDGL maintains a biweekly production schedule of yttrium-90 hydrogel to ensure steady treatment supply.